NEWS: CEO update on 9/26. Moves higher all week. Likely NVIV has, or is about to, lift the self imposed pause on the Clinical Trial. Good time to add or buy back in, imo. Link: http://www.businesswire.com/news/home/20170920005356/en/InVivo-Therapeutics-Present-Ladenburg-Thalmann-2017-Healthcare